Product name
|
Imatinib Mesylate
|
Molecular Formula
|
C30H35N7O4S
|
Molecular Weight
|
589.71
|
CAS No.
|
220127-57-1
|
Quality Standard
|
In-house
standard
|
Appearance
|
White powder
|
TEST ITEMS
|
SPECIFICATION
|
RESULTS
|
Appearance
|
White or slightly yellow crystalline powder,
homogeneous and with fine grain size.
No foreign particles are observed.
|
Slightly yellow crystalline Powder
|
Solubility
|
Soluble in water and in acids solutions, slightly
soluble
in methanol insoluble in acetone, acetonitrile and
dilute hydroxyl alkaline solution
|
Confirm
|
Identification
|
Complies
|
Confirm
|
Water
|
≤1.0%
|
0.8%
|
Heavy metals
|
≤20ppm
|
10ppm
|
Melting range
|
212 – 220℃
|
214-216℃
|
Residue on ignition
|
≤0.1%
|
0.08%
|
Particle size
|
90% < 100 μm
50% < 50 μm
|
Confirm
|
Bulk density
|
NLT 0.4g/ml
|
0.6g/ml
|
Chromatographic
purity
|
Individual impurities: ≤0.2%
Total impurities: ≤0.5%
|
0.16%
0.32%
|
Assay
|
98.5%-102.0% of Imatinib mesylate,
calculated on anhydrous basis.
|
99.70%
|
Residual solvents
|
Ethyl acetate: ≤5000ppm
|
Confirm
|
Acetone: ≤5000ppm
|
Confirm
|
N,N-Dimethylformamide: ≤880ppm
|
Confirm
|
Methanol: ≤3000ppm
|
Confirm
|
Dichloromethane: ≤300ppm
|
Confirm
|
We provide you
with high-quality imatinib mesylate
powder and imatinib mesylate
price is very reasonable and competitive.
Imatinib mesylate (also called Gleevec) is a
small-molecule inhibitor of the fusion protein Bcr-Abl,
the causal agent in
chronic myelogenous leukemia.
As an inhibitor of
PDGFR, imatinib mesylate appears to
have utility in the treatment of a variety of
dermatological
diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+
mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma
protuberans.
1. A tyrosine kinase inhibitor. Highly
specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia
(CML) and certain forms of acute lymphoblastic leukemia (ALL)
2. Echinocandin antifungal, active
against infections with Aspergillus and Candida, inhibits cell wall synthesis
3. Anticancer